RE:RE:RE:RE:RE:RE:RE:RE:Questions for the company.I'm not against asking questions about the SP, but I can't pretend that everything is rosy and there's no real questions on what's dragging out testing.
Spectral is a company that is shepherding other company's inventions (Toray= PMX, Infomed= SAMI/DIMI) through FDA testing in order to sell them in the US.
As of Spectral's Nov. 12 update
The Tigris trial (in it's 32nd month) has enrolled 25 patients out of the 150 needed.
(Begining of Tigris March 2019)
In May Spectral announced the DIMI 35 person usability trial to start in Q3 which has now been "postponed" to start end of Q1.
It's maddening, and the SP is a reflection of what they have delivered on what they promised. They need to prove to investors they can deliver without adding years, more financing, dilution, etc.
If Tigris was at 90 patients we'd be dancing to a very different tune.